Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
Saghir Akhtar, Ibrahim F. Benter, Mohammed Danjuma, Suhail A.R. Doi, Syed Shahzad Hasan, Abdella M. Habib
Abstract
and the available literature on the clinical safety of these drugs in COVID-19 patients. Further, in a re-analysis of clinical data from a meta-analysis of 9 studies, we show that ACEIs/ARBs usage was not associated with an increased risk of all-cause mortality. Literature suggests that ACEIs/ARBs usage generally appears to be clinically safe though their use in severe COVID-19 patients might increase the risk of acute renal injury. For definitive clarity, further clinical and mechanistic studies are needed in assessing the safety of all classes of ACE2 raising medications.
Topics & Concepts
MedicinePharmacotherapyDiabetes mellitusCoronavirus disease 2019 (COVID-19)Adverse effectPharmacologyIntensive care medicineDrugInternal medicineDiseaseEndocrinologyInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19